The Chemours Company (NYSE:CC) Given Average Recommendation of “Hold” by Brokerages

The Chemours Company (NYSE:CC) has earned an average rating of “Hold” from the eight analysts that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $24.88.

CC has been the topic of several recent research reports. JPMorgan Chase & Co. lowered their price objective on Chemours from $25.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th. The Goldman Sachs Group decreased their target price on Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 3rd. BMO Capital Markets increased their target price on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Morgan Stanley decreased their target price on Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 5th. Finally, UBS Group decreased their target price on Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th.

Chemours Trading Down 0.7 %

Chemours stock opened at $19.16 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. Chemours has a 12 month low of $15.10 and a 12 month high of $32.70. The stock’s 50 day simple moving average is $19.07 and its two-hundred day simple moving average is $21.88. The firm has a market cap of $2.86 billion, a PE ratio of 38.32 and a beta of 1.75.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the prior year, the firm posted $0.64 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. Analysts anticipate that Chemours will post 1.35 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 5.22%. The ex-dividend date is Friday, November 15th. Chemours’s dividend payout ratio is currently 200.00%.

Insider Activity at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at approximately $343,552.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is owned by corporate insiders.

Institutional Trading of Chemours

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Brooklyn Investment Group acquired a new stake in shares of Chemours in the 3rd quarter worth $37,000. FMR LLC increased its stake in shares of Chemours by 3.5% in the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock worth $368,650,000 after acquiring an additional 618,361 shares during the last quarter. Truvestments Capital LLC purchased a new position in shares of Chemours during the 3rd quarter worth $35,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Chemours by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company’s stock worth $24,974,000 after purchasing an additional 32,590 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Chemours during the 3rd quarter worth $207,000. 76.26% of the stock is owned by institutional investors and hedge funds.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.